| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
242,830,000 |
| Market
Cap: |
573.08(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.39 - $3.86 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Lyell Immunopharma is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Co. is building a multi-modality product pipeline. Co.'s primary activities include developing T cell therapies, performing research and development, acquiring technology, entering into strategic collaboration and license arrangements, enabling manufacturing activities in support of its product candidate development efforts, organizing and staffing Co., establishing its intellectual property portfolio, regulatory submissions and other preparations to initiate clinical trials, raising capital and providing general and administrative support for these activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
58,020 |
69,120 |
| Total Sell Value |
$0 |
$0 |
$132,286 |
$203,327 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
2 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Newton Charles W. |
Chief Financial Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
48,729 |
|
- |
|
| Seely Lynn |
President and CEO |
• • – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
| Lee Gary K. |
Chief Scientific Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
52,700 |
|
- |
|
| Hill Stephen J. |
Chief Operating Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
48,928 |
|
- |
|
| Lang Matthew |
Chief Business Officer |
• – – |
2024-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
| Klausner Richard |
Director |
– • – |
2023-08-15 |
4 |
S |
$2.28 |
$132,286 |
I/I |
(58,020) |
930,880 |
|
13% |
|
| Klausner Richard |
Director |
– • – |
2022-09-23 |
4 |
S |
$6.40 |
$71,041 |
I/I |
(11,100) |
988,900 |
|
48% |
|
| Bishop Hans Edgar |
Director |
– • – |
2022-09-08 |
4 |
OE |
$0.10 |
$14,538 |
D/D |
145,380 |
4,685,614 |
|
- |
|
| Bishop Hans Edgar |
Director |
– • – |
2022-02-23 |
4 |
OE |
$0.10 |
$99,343 |
D/D |
993,428 |
4,540,234 |
|
- |
|
| Friedman Cathy |
Director |
– • – |
2021-12-14 |
4 |
A |
$0.00 |
$0 |
I/I |
218,722 |
236,370 |
|
- |
|
| Friedman Cathy |
Director |
– • – |
2021-12-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(3,765,842) |
0 |
|
- |
|
| Bishop Hans Edgar |
Director |
– • – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
546,806 |
3,546,806 |
|
- |
|
| Klausner Richard |
Executive Chairman |
• • – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,765,842 |
3,765,842 |
|
- |
|
| Bybee Clinton |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
36,412,716 |
18,206,358 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
36,412,716 |
18,206,358 |
|
- |
|
| Friedman Cathy |
Director |
– • – |
2021-06-21 |
4 |
B |
$17.00 |
$300,016 |
I/I |
17,648 |
17,648 |
2.1 |
-14% |
|
| Friedman Cathy |
Director |
– • – |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,765,842 |
3,765,842 |
|
- |
|
| Glaxosmithkline Plc |
10% Owner |
– – • |
2021-06-21 |
4 |
A |
$0.00 |
$0 |
I/I |
30,253,189 |
30,253,189 |
|
- |
|
18 Records found
|
1
|
Page 1 of 1 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.04 (1.67%) 
